Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer

Silas Inman @silasinman
Published: Tuesday, Apr 19, 2016

Dr Maura Gillison

Maura Gillison, MD, PhD

Treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN), according to findings from the phase III CheckMate-141 study presented at the 2016 AACR Annual Meeting.

Median OS with nivolumab was 7.5 months compared with 5.1 months with investigator's choice of therapy (HR, 0.70; 95% CI, 0.51-0.96; P = .0101). Additionally, the 1-year OS rates were 36% with nivolumab compared with 16.6% for investigator’s choice. Adverse events (AEs) were significantly less with nivolumab versus investigator's choice, specifically for grade 3/4 events (13.1% vs 35.1%).

“What we think is most important about this trial is the number of patients who survive for a year, which is doubled with nivolumab in comparison with investigator’s choice. There was a 20% absolute improvement, which is something that has never been seen in this patient population before,” said lead investigator Maura Gillison, MD, PhD, Jeg Coughlin Chair of Cancer Research, The Ohio State University Wexner Medical Center. “Nivolumab represents a new standard of care option for patients with relapsed/metastatic head and neck cancer after platinum-based chemotherapy.”

In the trial, 361 patients with cancer of the oral cavity, pharynx, or larynx were randomized in a 2:1 ratio to receive nivolumab (n = 240) or investigator's choice of cetuximab, methotrexate, or docetaxel (n = 121). Nivolumab was administered intravenously at 3 mg/kg every 2 weeks. Cetuximab was administered at 400 mg/m2 for the first dose followed by 250 mg/m2 weekly. Methotrexate was administered at 40 mg/m2 weekly. Docetaxel was administered at 30 mg/m2 weekly.

The primary endpoint was OS, with secondary outcome measures focused on response rates and progression-free survival (PFS). The study was initiated in May 2014 and was not scheduled to complete until October 2016; however, it was stopped early after an independent monitoring panel determined the primary endpoint was met with the anti–PD-1 agent versus the investigator's choice of therapy.

The median age of patients in the trial was 60 years, and 31.3% were ≥65 years of age. The majority of patients were male (83%), Caucasian (83%), and had an ECOG PS of 1 (78.4%). Most patients received ≥2 prior systemic therapies (54.8%), and over 90% had received prior radiation therapy. Patients were stratified based on prior cetuximab therapy, and HPV status was known for 49.3% of patients. 

Findings were not presented at the conference for objective response rates and PFS. The only efficacy endpoint released during the session was OS, which was the primary focus of the interim analysis that led to the halting of the study.

“Nivolumab is the first agent to demonstrate a significant improvement in survival in patients with head and neck cancer that has progressed after platinum-based chemotherapy that was demonstrated in this randomized, phase III comparative trial,” said Gillison. “This fulfills an incredible unmet need in the clinic.”

Improvements in OS with nivolumab varied, based on HPV status. In the HPV-positive group, the median OS was 9.1 months with nivolumab compared with 4.4 months with investigator's choice (HR, 0.56; 95% CI, 0.32-0.99). In the HPV-negative arm, the median OS with nivolumab was 7.5 versus 5.8 months (HR, 0.73; 95% CI, 0.42-1.25).

PD-L1 expression, which was available for 72% of enrolled patients, was associated with response to nivolumab. Those with PD-L1 expression on ≥1% of cells experienced a median OS of 8.7 months with nivolumab compared with 4.6 months in the control arm (HR, 0.55; 95% CI, 0.36-0.83). In those with PD-L1 expression of <1%, the median OS was 5.7 versus 5.8 months, for nivolumab and the control arm, respectively (HR, 0.89; 95% CI, 0.54-1.45).

“Nivolumab provided survival benefits in all of these subgroups; however, the magnitude of the reduction in the risk of death was greater for patients whose tumors expressed PD-L1 in greater than 1% of cells or were HPV-positive,” said Gillison. “In those two groups, the risk of death was reduced by approximately half.”

All-grade AEs were experience by 58.9% of patients treated with nivolumab compared with 77.5% with investigator's choice. The most common grade 3/4 AEs with nivolumab were fatigue (2.1%), anemia (1.3%), and asthenia (0.4%). For investigator's choice, the most common grade 3/4 AEs were anemia (4.5%), alopecia (2.7%), fatigue (2.7%), diarrhea (1.8%), asthenia (1.8%), and mucosal inflammation (1.8%).


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder CancersAug 31, 20182.0
Publication Bottom Border
Border Publication
x